ReviewFrontiers in immunology2026
SEC61: a potential therapeutic target in transplantation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.Cancer biology & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SEC61 translocon complex has emerged as a multifunctional therapeutic target linking protein secretion, calcium homeostasis, and immune regulation in kidney transplantation. Beyond canonical protein translocation, SEC61 regulates antigen cross-presentation, cytokine secretion (IL-2, IFN-γ, TNF-α), surface activation molecules (CD62L), and functions as an endoplasmic reticulum calcium-leak channel that modulates unfolded protein response activation under specific physiological and stress conditions. During ischemia-reperfusion injury, ATP depletion impairs SERCA-mediated calcium reuptake while SEC61-mediated calcium efflux persists, triggering ER stress and tubular injury. Selective pharmacological SEC61 inhibition has been proposed to confer multiple immunomodulatory and cytoprotective effects - including reduced antigen cross-presentation, suppression of high-burden secretory lymphocytes, limited T cell migration, and intrinsic antiviral activity through blockade of envelope glycoprotein biogenesis-based on mechanistic and preclinical evidence, although these effects remain to be validated in transplant-specific models. Emerging phase I oncology data with client-selective inhibitors demonstrate the feasibility of pharmacologic SEC61 modulation in humans, although the safety, dosing, and patient population in transplantation may differ substantially from oncology settings. This review examines SEC61's multifaceted roles in transplant immunobiology and its therapeutic potential as a novel immunomodulatory target in kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.